Randomised, Double-blind, 56 Week Placebo-controlled, Parallel Group, Multicentre, Phase 3 Study to Evaluate the Efficacy and Safety of 2 Doses of Benralizumab in Patients With Moderate to Very Severe COPD With a History of Exacerbations
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 29 Nov 2017
At a glance
- Drugs Benralizumab (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms GALATHEA
- Sponsors AstraZeneca
- 07 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 27 Jan 2017 Planned End Date changed from 1 May 2018 to 1 Apr 2018.
- 27 Jan 2017 Planned primary completion date changed from 1 May 2018 to 1 Apr 2018.